Metformin is always used as the baseline antidiabetic therapy for patients with type 2 diabetes mellitus (T2DM) and hyperuricemia. Metformin is excreted into urine through active secretion mediated by rOCTs and rMATE1.The aim of this study was to identify the effects of high uric acid on the disposition and its mechanism. For the in vivo study, a hyperuricemic animal model was induced by intraperitoneal injection of potassium oxonate (250 mg/kg) in rats. Metformin (100 mg/kg) was administered orally to investigate the pharmacokinetics in control and hyperuricemic rats, respectively. For the in vitro study, HEK293 and HepaRG cells were used to investigate the effect of uric acid (15 mg/dl) on the expression of OCT1, OCT2 and MATE1 and the disposition of metformin, respectively. The in vivo study showed that the AUC 0 → 600 of metformin was significantly decreased by 33.3%, whereas the cumulative urinary excretion of metformin was increased by 25.4% in hyperuricemic rats compared with that in control rats. The renal rOCT1, rOCT2 and rMATE1 and hepatic rMATE1 levels were increased in hyperuricemic rats compared with those in control rats, respectively. The in vitro study showed that uric acid could upregulate the expression of OCT2 and MATE1 in HEK293 cells and MATE1 in HepaRG cells and increase the intracellular metformin concentration in these two cell lines. These results demonstrated that a high uric acid level promoted urinary metformin excretion and decreased the plasma metformin concentration; the in vivo and in vitro studies provided a possible explanation being that high uric acid could upregulate the expression of renal metformin transporters OCTs and MATE1. 
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| INTRODUCTION
Hyperuricemia, an increase in serum uric acid levels above the normal range, is a recognized feature of the metabolic syndrome and is always related to renal dysfunction (Dankers et al., 2013; Hu et al., 2013) .
Recent evidence suggests that hyperuricemia contributes to the development of T2DM, which was identified as another consequence of hyperuricemia (Bartakova et al., 2016; Dehghan, van Hoek, Sijbrands, Hofman, & Witteman, 2008) . The coincidence of hyperuricemia and T2DM was 32.6% in 2917 Chinese patients (Wang et al., 2013 ) and 25% in 601 Nigerian patients (Ogbera & Azenabor, 2010) , respectively. These data clearly show that hyperuricemia is strongly associated with T2DM and its clinical importance should not be overlooked. Metformin is always used in the baseline antidiabetic therapy of patients with T2DM and hyperuricemia (Vitale, Cantarini, Rigante, Bardelli, & Galeazzi, 2015) , and belongs to the biguanide class of drugs (Clarke et al., 2015) . Metformin is not bound to plasma proteins and is excreted into urine via active secretion (about 78.9-99.9%) by the renal tubule cells in the unchanged form (Clarke et al., 2015; Silva et al., 2013) . In vitro and in vivo studies have implicated that the active secretion of metformin is mediated by renal organic cation transporter 1 (OCT1/ SLC22A1) and OCT2/SLC22A2 on the basolateral membrane of proximal tubule cells and multidrug and toxin extrusion 1 (MATE1/SLC47A1) on the apical membrane (Becker et al., 2009; Clarke et al., 2015; Silva et al., 2013; Stocker et al., 2013) . OCT1 and OCT2 are located in the basolateral membrane of the renal epithelium and are responsible for the transportation of metformin over this membrane, which may be the first step to tubular secretion (Becker et al., 2009; Stocker et al., 2013) . In addition, OCT1 is also expressed in the basolateral membrane of hepatocytes and is the major determinant of metformin uptake into hepatocytes, being an essential step in its glucose-lowering effect (Becker et al., 2009 ).
MATE1 is located in the bile canalicular membrane of the hepatocytes and in the brush border of the renal epithelium, which is responsible for the final step of metformin excretion through the bile and urine (Becker et al., 2009; Silva et al., 2013) . However, there is no study providing information on the effect of hyperuricemia on the distribution and elimination of metformin.
Therefore, in vivo and in vitro studies were carried out to investigate the effect of high uric acid on the distribution of metformin. In the in vivo study, oxonate-induced hyperuricemic rats were used to investigate the metformin pharmacokinetics and its mechanism. In the in vitro study, human embryonic kidney epithelial HEK293 cells and human hepatoma HepaRG cells, both of which express uptake and efflux transporters of metformin, were used to investigate the effect of uric acids on the disposition of metformin.
| MATERIALS AND METHODS

| Materials
Metformin (97% purity) was obtained from Shouguang Fukang Pharmaceutical Co., Ltd. Oxonic acid potassium salt (97.5% purity, lot: L9B0F01) was purchased from J & K Chemical Ltd. MATE1 (S-14, sc-138983), OCT1 (C-21, sc-232) and OCT2 (H-62, sc-292622) were purchased from Santa Cruz Biotechnology, Inc. Methanol was of high-performance liquid chromatography (HPLC)-grade (Fisher Scientific, NJ, USA). All other chemicals and reagents were of analytical grade and were readily available from commercial sources.
| Animals and induction of hyperuricemic model
Male Wistar rats (180-220 g) were obtained from the Laboratory Animal Center of Lanzhou University. The animals were maintained on a 12 h light/dark cycle in an environment with controlled temperature (24 ± 1°C) and humidity (45 ± 5%) for a period of 1 week before use. Standard rat chow and water were available. Rats were fed with full valence granular rat feed stuff bought from the Laboratory Animal Center of Lanzhou University (Lanzhou, China).
The animal experimental protocols were reviewed and approved by the Institutional Animal Experimentation Committee of Lanzhou University. The rat hyperuricemic model of rat was developed according to the previous report (Silva et al., 2013) , and rats were treated with oxonic acid potassium salt (250 mg/kg) in intraperitoneal injection 2 hours before metformin administration.
| Animal experimental protocols
The first series of experiments aimed to develop the oxonic acidinduced hyperuricemic model. Twelve male rats were divided into a control group and a hyperuricemia group. Rats in the hyperuricemia group were treated with oxonic acid potassium salt (250 mg/kg, i.p.).
The rats were killed 2 hours after oxonic acid potassium salt injection.
Blood was collected for the determination of serum creatinine (SC), blood urea nitrogen (BUN) and serum uric acid (SUA) levels. After blood sample collection, the residual blood in the body was removed by saline cardiac perfusion, and then liver and kidney were harvested immediately. A piece of the kidney was immediately fixed in 10% neutral buffered formalin for 48 h and embedded in paraffin for histological evaluation. Liver and the rest of the kidney tissues were frozen in liquid nitrogen and stored at −80°C for western blotting.
The second series of experiments was designed to investigate the effect of hyperuricemia on the pharmacokinetic profile of metformin.
Rats which were divided into two groups, the hyperuricemia group were treated with oxonic acid potassium salt (250 mg/kg) 2 hours before metformin (100 mg/kg) administration, while rats in the control group were treated with metformin (100 mg/kg). Serial blood samples (0.25 ml) were collected from the right side of the femoral artery with heparinized syringes at 0, 10, 20, 40, 60, 90, 120, 180, 240, 360, 480 and 600 min after the final metformin administration, respectively.
The plasma concentration of metformin was determined by HPLC, and the pharmacokinetic parameters were calculated using the DAS2.0 program.
The third series of experiments was designed to test the effect of hyperuricemia on the renal clearance of metformin. The group setting and drug treatments were the same as that for the metformin pharmacokinetics studies. Urine samples were gathered during intervals of 0-2, 2-4, 4-6, 6-8, 8-10, 10-12 and 12-24 h post metformin administration.
The final series of experiments was intended to investigate the effect of hyperuricemia on the tissue distribution of metformin. The group setting and drug administrations were the same as that for the oral pharmacokinetics study, but the rats were killed at 2 h post metformin. Tissues (heart, liver, brain, lung, kidney and small intestine) were dissected, weighed and homogenized in saline for the determination of metformin after the blood in the body had been removed by saline cardiac perfusion.
| Renal function evaluation and histopathological analysis
Renal function was evaluated by SC, BUN and SUA levels using a biochemical autoanalyser (Olympus AU2700, Olympus Co., Tokyo, Japan). Formalin-fixed and paraffin embedded kidney tissues were stained with hematoxylin and eosin (H&E) and analysed by a pathologist.
| Cell culture and treatments
To validate the effect of hyperuricemia, not oxonic acid, on the expression of renal OCT1, OCT2 and MATE1, we further investigated the effect of uric acid on the expression of OCT2 and MATE1 and the intracellular metformin in HEK293 and HepaRG cells, respectively. HepaRG and HEK293 cells were obtained from Invitrogen and the Type Culture Collection of the Chinese Academy of Sciences, respectively. HepaRG cells were cultured in RPMI 1640 medium (Hyclone), while HEK293 cells were cultured in DMEM (high glucose) medium (Hyclone). Both cell lines had been cultured at 37°C in a humidified atmosphere containing 5% CO 2 , the cell culture media had been supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. To examine the effects of uric acid on the intracellular concentration of metformin and hepatic OCT1, MATE1 and renal OCT2, MATE1, HepaRG and HEK cells were exposed to uric acid (900 μmol/l; corresponding to 15 mg/dl) for 2 h, respectively. The medium was aspirated, and the cells were washed three times with ice-cold phosphatebuffered saline (PBS), and then half of the cells were added to the culture medium containing 20 μg/ml metformin. The cells were collected and lysed by methanol after 5, 15 and 30 min. The lysate was subsequently used to determine the intracellular concentration of metformin by HPLC; and half of cells were collected and lysed by RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1.0% nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, and PMSF), and the lysates were stored at −80°C for western blotting.
| Hematoxylin-eosin (HE), immunofluorescence (IF) and TUNEL staining
Hematoxylin-eosin and immunofluorescence staining were used to observe changes in the cellular morphology after uric acid treatment for 2 hours. The HE staining was performed as follows. The cells were fixed for 20 min in 95% ethanol, and then dyed with hematoxylin and eosin. The IF staining was performed as in a previous report (Markmiller et al., 2018) . The HEK293 and Hepa RG cells were incubated with primary antibodies against mouse monoclonal to β-actin (dilution 1:100, cat. ab8226, Abcam) and antibodies against rabbit polyclonal to β-actin (dilution 1:100, cat. ab8227, Abcam), respectively. Cy3-labeled goat anti-mouse lgG (H + L) (dilution 1:500, cat. A0521, Beyotime) and FITClabeled goat anti-rabbit lgG (H + L) (dilution 1:500, cat. A0562, Beyotime) were used as the second antibody, respectively. 4′,6-Diamidino-2-phenylindole (DAPI staining solution, C1005, Beyotime, China) was used to label the nucleus (room temperature for 5 min). Fluorescence staining was viewed by a microscope (Carl Zeiss, Axio Imager Z2, Germany).
The HepaRG or HEK293 cell apoptosis after uric acid treatment for 2 hours was determined using a TUNEL fluorescence FITC kit 
| Sample preparation and HPLC analysis
The method was used as previously reported in our laboratory (Ma et al., 2015) . Briefly, blood, urine and tissues were collected and analysed by HPLC, respectively (LC-20A, Shimadzu Inc., Kyoto, Japan).
Separation was performed on an Agilent HC-C18 column 250 mm × 4.0 mm i.d., 5 μm (Agilent Technology Inc., CA, USA). The mobile phase consisted of a mixture of 57% methanol and 43% water with 2 mmol/l sodium dodecyl sulfate, 0.1% triethylamine and 0.08% phosphate. The flow rate and column temperatures were 1.0 ml/min and 40°C, respectively. The wavelength was set at 235 nm.
| Western blot analysis
Liver and kidney tissues were homogenized in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1.0% nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, and PMSF) and centrifuged at 14,000 × g for 10 min at 4°C, the supernatants were harvested, respectively. After the determination of protein content, the samples were denatured at 100°C for 5 min. The samples were separated on 10% SDS-PAGE gel and transferred to PVDF membrane (Millipore, 0.45 μm). Nonspecific binding sites were blocked with 5% nonfat milk for 2 h at room temperature, and then the mem- software. In order to adjust for any variations in loading, all detected protein bands were normalized to GAPDH levels.
| Immunohistochemical analysis
Immunohistochemical analysis was performed by the DAB method as described previously (Zhang et al., 2016) . Antigens were unmasked by microwaving sections in 10 mmol/l citrate buffer, pH 6.0 (25 minutes), and immunostaining was undertaken using the streptavidin-biotinenzyme complex method with antibodies against OCT1, OCT2 and MATE1 at a concentration of 2 μg/ml, respectively, and equivalent concentrations of polyclonal nonimmune IgG controls. After incubation with the appropriate biotin-conjugated secondary antibody and subsequently with streptavidin solution, color development was performed using 3,3-diaminobenzidine tetrahydrochloride (DAB) as a chromogen. Sections were counterstained using hematoxylin. After staining, the sections were dehydrated through increasing concentrations of ethanol and xylene. The immune reaction products were observed under a light Leica microscope equipped with a Leica color digital camera system. Images were captured with 40× and analysed using ImageJ 1.37c software by an investigator blinded to the sample groups.
| Statistical analysis
All results are represented as mean ± standard derivation (SD). Statistically significant differences of data from the two sets were compared using Student's t-test (St) by Microsoft Excel 2007. In all statistical analyses, p < 0.05 or p < 0.01 were considered to indicate a statistically significant result.
| RESULTS
| Renal function and pathology in oxonic acid-induced hyperuricemic rats
Renal function and pathology were first examined in rats with oxonic acid-induced hyperuricemia. As shown in Figure 1 , no evidence of kidney injury was found in oxonic acid-induced hyperuricemic rats ( Figure 1a) . Although there were no changes in plasma blood urea nitrogen and serum creatinine levels, the hyperuricemic rats had dramatically higher serum uric acid levels than in the control group (Figure 1b) , indicating that the hyperuricemic model was evoked by oxonic acid treatment.
| Effects of oxonic acid-induced hyperuricemia on metformin pharmacokinetics and tissue distribution
To determine the effects of hyperuricemia on metformin disposition, an oral pharmacokinetic study was performed. The plasma concentration-time profile of metformin up to 600 min after oral administration is shown in Figure 2 .The plasma concentration of metformin in hyperuricemic rats was lower than that in the control rats ( Figure 2a) . The main relevant pharmacokinetic parameters are listed in Table 1 . The AUC and C max for metformin in hyperuricemic rats were significantly decreased compared with that of the control group.
The V d /F, CL/F and K e values for metformin in hyperuricemic rats were significantly increased by 76%, 57% and 33%, respectively, of the corresponding values in control rats. No significant differences were observed in t 1/2α , t 1/2β , T max and k a of metformin between the hyperuricemic rats and control rats. Figure 2b , c shows the tissue distribution and tissue-to-plasma concentration ratio (K p ) for metformin in hyperuricemic and control rats at 120 min after p.o. administration, respectively. Concentrations of metformin in the liver and kidney were significantly decreased in the hyperuricemic rats compared with that in the control rats, whereas there were no significant differences in the intestine, heart, spleen, lung and brain concentrations of metformin between hyperuricemic and control rats. However, no significant differences were found in intestine, liver, kidney, heart, spleen, lung and brain K p value between the hyperuricemic rats and control rats.
| Effect of oxonic acid-induced hyperuricemia on urinary excretion of metformin
Metformin is mainly excreted into urine in an unchanged form, therefore, we assessed the urinary excretion of metformin. The cumulative urinary excretion rate of metformin up to 24 h after oral FIGURE 1 Renal pathological analyses (a) and renal functional data (b) at 2 h after oxonic acid treatment. The amplification of kidney pathology was 200×. Each point represents the mean ± SD from six rats. ***p < 0.001, versus control rats administration is displayed in Figure 3 . The urinary excretion of metformin in hyperuricemic rats was higher than that in control rats.
| Protein expression of rOCT1, rOCT2 and rMATE1 in oxonic acid-induced hyperuricemic rats
To obtain precise information about increases in the excretion of metformin in urine of hyperuricemic rats, we measured renal rOCT1, rOCT2 and rMATE1 expression using western blot and immunohistochemistry analyses, respectively. As is evident from Figure 4a , rOCT1, rOCT2 and rMATE1protein expression in hyperuricemic rats were markedly increased by 242%, 33% and 199%, respectively, of the corresponding values in control rats. Immunohistochemistry analyses showed that rOCT1, rOCT2 and rMATE1 protein expression were elevated as well in hyperuricemic rats compared with that in control rats (Figure 4b ).
The hepatic distribution of metformin is necessary for its inhibition of gluconeogenesis, therefore, we measured the main hepatic metformin transporters rOCT1and rMATE1 expression using western blot analyses. As shown in Figure 4c , rMATE1 protein expression was markedly elevated in hyperuricemic rat liver compared with that in control rat liver, whereas there was no significant difference in the expression of rOCT1.
| Effect of uric acid on morphological changes of HEK293 and HepaRG cells
Immunofluorescence and hematoxylin-eosin staining were used to label the morphological changes of HEK293 and HepaRG cells. The results of staining are shown in Figure 5 . No significant structural changes were observed after uric acid treatment for 2 hours, either in HEK293 or HepaRG cells.
| Effect of uric acid on HEK293 and HepaRG cell apoptosis
The toxicity of uric acid to HEK293 and HepaRG cells was evaluated by the TUNEL staining. The result is shown in Figure 6 . The apoptosis of HEK293 and HepaRG cells was significantly increased after uric acid treatment for 2 hours, respectively. FIGURE 2 Effects of oxonic acid-induced hyperuricemia on metformin pharmacokinetics and tissue distribution. Panel (a) depicts the plasma concentration versus time profiles for metformin up to 600 min in control rats (○) and hyperuricemic rats (•) after p.o. administration of metformin (100 mg/kg). Panels (b) and (c) depict the intestine, liver, kidney, heart, spleen, lung and brain concentration and the tissue-to-plasma concentration ratio (K p ) for metformin in hyperuricemic (■) and control rats (□) at 120 min after p.o. administration, respectively. Each point represents the mean ± SD from six rats. *p < 0.05, **p < 0.01, versus control rats 3.7 | Effect of uric acid on OCT1, OCT2 and MATE1 expression and metformin uptake in HEK293 and HepaRG cells
The effect of uric acid on the OCT1, OCT2 and MATE1 expression and the intracellular metformin of HEK293 and HepaRG cells were analysed by western blot and HPLC, respectively. The OCT2 and MATE1 were significant increased after uric acid treatment for 2 hours in HEK293 cells (Figure 7a ), while MATE1 was significant increased and OCT1 showed no significant change after uric acid treatment for 2 hours in HepaRG cells (Figure 7b ). The levels of intracellular metformin within 5, 15, and 30 minutes were significantly increased after uric acids for 2 hours in HEK293 and HepaRG cells, respectively.
| DISCUSSION
Hyperuricemia, an increase in serum uric acid levels above the normal range, has been defined as a component of metabolic syndrome . Each point represents the mean ± SD from six rats. *p < 0.05, **p < 0.01, versus control rats FIGURE 4 Protein expression of rOCT1, rOCT2 and rMATE1 in oxonic acid-induced control and hyperuricemic rats. Panel (a) depicts the antisera specific for renal rOCT1, rOCT2 and rMATE1, GAPDH were used as primary antibodies in western bloting (a1) and the ratio of rOCT1, rOCT2 and rMATE1 density to GAPDH density in control (□) and hyperuricemic rats (■) (a2). Panel (b) depicts the antisera specific for renal tubular rOCT1, rOCT2 and rMATE1 were used as primary antibodies in immunohistochemistry (b1) and the renal positive expression of rOCT1, rOCT2 and rMATE1 in control (□) and hyperuricemic rats (■) (b2). Panel (c) depicts the antisera specific for renal rOCT1, rMATE1 and GAPDH were used as primary antibodies in western blotting (c1) and the ratio of rOCT1 and rMATE1 density to GAPDH density in control (□) and hyperuricemic rats (■) (c2). Each point represents the mean ± SD from six rats. *p < 0.05, **p < 0.01, versus control rats (Dankers et al., 2013) . Elevated SUA levels may contribute to the development and progression of chronic kidney disease (Prasad Sah & Qing, 2015) . Oxonic acid, a uricase inhibitor, is most frequently employed to develop an animal model of hyperuricemia (Johnson, Stavric, & Chartrand, 1969; Shi et al., 2016; Silva et al., 2013) . In our study, we used oxonic acid potassium salt (250 mg/kg, i.p.) to develop the hyperuricemic model, and found the SUA level was increased in hyperuricemic rats compared with that in control rats, whereas there were no significant differences in BUN and SC levels (Figure 1 ), consistent with the previous report (Silva et al., 2013) .
Metformin is always used as the baseline antidiabetic therapy of patients with T2DM and hyperuricemia (Vitale et al., 2015) . The present study demonstrated that the AUC of orally administered metformin in hyperuricemic rats was decreased compared with that in control rats (Table 1) . Pharmacokinetics analyses showed elevated CL/F, V d /F, and K e of metformin in hyperuricemic rats compared with those in control rats (Table 1 ). These findings suggest that the decreased AUC of metformin in hyperuricemic rats could be attributable to the apparent elevated clearance of metformin. We next examined the tissue distribution and urinary excretion of metformin, respectively. The hepatic and renal concentration of metformin in hyperuricemic rats was significantly decreased compared with that of in control rats (Figure 1 ), whereas there were no significant differences in the hepatic and renal K p values between hyperuricemic and control rats. The urinary excretion of metformin was markedly increased in hyperuricemic rats compared with that in control rats.
These finds strongly indicate that the decreased AUC of metformin is mainly caused by the increased urinary excretion of metformin, and these results further support the idea of decreased hepatic and renal concentration of metformin may cause by the decreased plasma concentration of metformin.
Metformin is known to be a substrate for rat rOCT1, rOCT2 and rMATE1. The OCTs regulate metformin uptake at the basolateral membranes of hepatocytes (rOCT1) and proximal tubule cells (rOCT1, showed that changes in expression and function of these transporters can dramatically affect the pharmacokinetics of metformin (Higgins, Bedwell, & Zamek-Gliszczynski, 2012; Wang & Weinshilboum, 2014) . In the present study, renal rOCT1, rOCT2 and rMATE1 protein expression in hyperuricemic rats were markedly elevated in hyperuricemic rats compared with that in control rats (Figure 4a, b) .
Most of the unchanged metformin is excreted into urine via a process of rOCT1 and rOCT2 uptake and rMATE1 efflux (Clarke et al., 2015; Silva et al., 2013) . Therefore, in the present study, the main cause of decreased metformin in the organism could be attributed to increased renal rOCT1, rOCT2 and rMATE1 expression, which may promote the urinary excretion of metformin in hyperuricemic rats. However, the result is different from a previous report which found that the protein levels of mice renal mOCT1 and mOCT2 were reduced after oxonic acid (250 mg/kg) treatment for 7 consecutive days (Hu et al., 2013) .
The main differences between the two studies were the oxonic acid treatment time, this result seeming to provide a chronic hyperuricemic model, whereas our results provided more of an acute hyperuricemic model. However, further studies are required to clarify these issues.
To validate the effect of hyperuricemia, not oxonic acid, on the expression of renal OCT1, OCT2 and MATE1, we further investigated the effect of uric acid on the expression of OCT2 and MATE1 and the intracellular metformin in HEK293 cells. The OCT2 and MATE1 and the levels of intracellular metformin were significantly increased after uric acid for 2 hours in HEK293 cells (Figure 7a, c) , respectively. The result resembles that found in the animal study, suggesting that high uric acid could affect the disposition of metformin, caused by the upregulation of the major metformin transporters. Liver is not mainly an organ of metformin excretion, but the hepatic distribution of metformin is necessary for its inhibition of gluconeogenesis, therefore, we further investigated the expression of OCT1and MATE1 in rat liver and HepaRG cells. The rMATE1 protein expression was markedly elevated in hyperuricemic rat liver compared with that in the control rat liver, whereas there was no significant difference in the expression of rOCT1 (Figure 4c ), and the result was supported by the cell experiments ( Figure 7b ). However, the intracellular metformin of HepaRG cell was increased after uric acid treatment for 2 hours (Figure 7d ), A possible explanation for this might be that another metformin uptake transporter OCT3, only expressed in human liver (Wang & Weinshilboum, 2014) , was induced by uric acid. The results of this research support the idea that the high uric acid could reduce the concentration of plasma metformin through an increase in the renal rOCT1, rOCT2 and rMATE1 expression and promote the urinary metformin excretion. Although the safety of metformin allows a large area of use in clinical practice (Pollak, 2010) , the decreased plasma concentration of metformin may affect its curative effect in hyperuricemic patients with type 2 diabetes.
| CONCLUSION
Taken together, this study has shown that hyperuricemia could promote urinary metformin excretion and decrease the plasma metformin concentration, the in vivo and in vitro studies providing a possible explanation for this in that high uric acid could upregulate the expression of renal metformin transporters OCTs and MATE1. 
